Halozyme Therapeutics, Inc. HALO
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 45.03% | 41.15% | 39.12% | 37.55% | 31.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.03% | 41.15% | 39.12% | 37.55% | 31.19% |
| Cost of Revenue | 65.04% | 53.33% | 38.40% | 30.11% | 5.00% |
| Gross Profit | 39.68% | 37.75% | 39.34% | 39.84% | 40.56% |
| SG&A Expenses | 37.22% | 33.93% | 29.31% | 25.31% | 15.11% |
| Depreciation & Amortization | 57.52% | 40.98% | 24.44% | 7.90% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.50% | 45.01% | 33.35% | 25.11% | 7.46% |
| Operating Income | 38.53% | 38.35% | 43.82% | 48.02% | 54.59% |
| Income Before Tax | -12.19% | -15.72% | -16.79% | -16.20% | 55.37% |
| Income Tax Expenses | 12.73% | 25.88% | 29.24% | 32.68% | 71.69% |
| Earnings from Continuing Operations | -18.48% | -25.78% | -28.13% | -28.64% | 51.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.48% | -25.78% | -28.13% | -28.64% | 51.73% |
| EBIT | 38.53% | 38.35% | 43.82% | 48.02% | 54.59% |
| EBITDA | 40.22% | 38.50% | 41.56% | 43.18% | 47.07% |
| EPS Basic | -14.29% | -21.44% | -24.20% | -25.45% | 59.02% |
| Normalized Basic EPS | 41.80% | 43.83% | 51.30% | 57.19% | 63.55% |
| EPS Diluted | -17.36% | -23.45% | -26.19% | -27.54% | 57.13% |
| Normalized Diluted EPS | 40.56% | 43.30% | 51.01% | 56.91% | 61.90% |
| Average Basic Shares Outstanding | -4.36% | -5.53% | -5.80% | -5.49% | -4.27% |
| Average Diluted Shares Outstanding | -3.53% | -5.06% | -5.43% | -5.11% | -3.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |